mProX™ Human EPOR Stable Cell Line

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;UT-7;A2780;H1299

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research

Related Diseases

Erythrocytosis, Familial, 1; Erythroleukemia

Gene ID

Human:2057

UniProt ID

Human:P19235

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

EPOR (erythropoietin receptor) has been studied in various medical contexts. In lung adenocarcinoma (LUAD), EPOR expression has been found to be down-regulated at the mRNA levels and up-regulated at the protein levels, indicating inconsistency between mRNA and protein levels. EPOR has also been associated with oxidative stress-related genes and prognosis in LUAD patients, suggesting its potential as a prognostic marker. In B-cell acute lymphoblastic leukemia (B-ALL), EPOR has been detected in gene fusions involving the Immunoglobulin Heavy Chain (IGH) locus, and its detection rates have been optimized using bioinformatics analysis workflows. In Philadelphia chromosome-like B-ALL, a surrogate molecular approach involving EPOR has been proposed for the detection of this high-risk genetic subtype. In memory and learning, EPOR expression has been induced in memory-relevant brain areas, and exogenously applied EPO (erythropoietin) has been found to promote remote memory consolidation. In traumatic brain injury (TBI), recombinant EPO has been shown to induce oligodendrocyte progenitor cell (OPC) proliferation, potentially enhancing remyelination and promoting myelination after TBI.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human EPOR Stable Cell Line (S01YF-1023-PY149). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Morgan Brown (Verified Customer)

What is the role of EPOR/JAK2 in acute erythroid leukemia? Feb 20 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

Amplified EPOR/JAK2 genes define a unique subtype of acute erythroid leukemia with activated STAT5 and aggressive clinical courses. Feb 20 2023

chat Taylor Garcia (Verified Customer)

How does EPOR signaling affect bone mass? Feb 13 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

EPOR signaling in osteoclast lineage contributes to EPO-induced bone loss, suggesting its role in bone mass regulation. Feb 13 2023

Published Data

Fig.1 Knocking down EpoR with siRNA had no impact on the survival of cancerous cells.

The impact of gene expression knockdown through siRNA was evaluated by assessing cell viability. For each siRNA, cell viability was normalized by dividing it by the median viability of cells transfected with roughly 10,000 unrelated siRNAs, where a value of 1.0 indicated no impact. Each data point signifies the normalized value for a specific siRNA, with a rectangular representation of the interquartile range (IQR) between the 25th and 75th percentiles. Whiskers extended from the minimum to the maximum value, unless the distance from the minimum to the first quartile exceeded 1.5 times the IQR, in which case, the whisker extended to the smallest value within 1.5 times the IQR from the first quartile. Similar rules applied for values larger than 1.5 times the IQR from the third quartile. The vertical bar represented the mean for siRNAs targeting specific genes. In each graph, the top plot represented PLK1 siRNA, the second plot JAK2 siRNA, the third plot EPOR siRNA, and the fourth and fifth plots in panels A and B CSFRA and CSFRB siRNA, respectively; the fourth plot in panels C-F and the sixth plot in panels A and B represented approximately 10,000 siRNAs targeting other genes. (A) UT-7/GM-CSF cells grown with rHuGM-CSF (Benjamin-Hochberg corrected P> .999 for EPOR). (B) UT-7/Epo cells grown with rHuEpo (P < .002). (C) A2780 cells grown without rHuEpo (P> .999). (D) A2780 cells grown with rHuEpo (P> .999). (E) NCI-H1299 cells grown without rHuEpo (P = .99). (F) NCI-H1299 cells grown with rHuEpo (P = .98).

Ref: Swift, Susan, et al. "Absence of functional EpoR expression in human tumor cell lines." Blood, The Journal of the American Society of Hematology 115.21 (2010): 4254-4263.

Pubmed: 20124514

DOI: 10.1182/blood-2009-10-248674

Research Highlights

Zhang, Yajing. et al. "Erythropoietin receptor is a risk factor for prognosis: A potential biomarker in lung adenocarcinoma." Pathology, research and practice, 2023.
Lung cancer, known for its highest mortality rate among all cancer types, presents a particularly grim survival outlook in cases of LUAD. Despite the presence of Erythropoietin receptor (EPOR) in LUAD, its expression levels and prognostic significance have remained unclear. A study involving 92 LUAD patients examined EPOR expression through various methods, including immunohistochemistry and bioinformatics databases. Findings revealed inconsistent mRNA and protein levels of EPOR, with notable differences in its expression among mutated and wild genes. Additionally, EPOR demonstrated correlations with oxidative stress-related genes and associations with VEGF, HIF family members, and prognosis in LUAD patients, suggesting its potential as a novel prognostic marker for the condition.
Zhang, Yajing. et al. "Erythropoietin receptor is a risk factor for prognosis: A potential biomarker in lung adenocarcinoma." Pathology, research and practice, 2023.
Pubmed: 37844485 DOI: 10.1016/j.prp.2023.154891

J Thomson, Ashlee. et al. "Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients." Cancers, 2023.
B-cell acute lymphoblastic leukaemia (B-ALL) is a type of cancer that is identified by various genetic modifications, with the most frequent being gene fusions detected through transcriptomic analysis. Detecting and understanding gene fusions involving the Immunoglobulin Heavy Chain (IGH) locus has been difficult due to the unpredictable changes they undergo.
J Thomson, Ashlee. et al. "Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients." Cancers, 2023.
Pubmed: 37835427 DOI: 10.3390/cancers15194731